STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway

Amy BeltonHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Lingling XianHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Tait HusoHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Michael KooHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

Li Z. LuoHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

James TurksonCell and Molecular Biology Department, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA;

Brent D. G. PageDepartment of Chemistry, University of Toronto, Ontario, Canada;

Patrick T. GunningDepartment of Chemistry, University of Toronto, Ontario, Canada;

Guosheng LiuDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;

David L. HusoDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ;Department of Oncology, Institute for Cellular Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USA

Linda M. S. ResarHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ;Department of Oncology, Institute for Cellular Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USACorrespondence[email protected]

show all

STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway

Articles from other publishers (11)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway

Citations (12)

Read on this site (1)

Articles from other publishers (11)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date